secwatch.observer — SEC 8-K summary
======================================

Issuer:     CARDINAL HEALTH INC (CAH)
CIK:        0000721371
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0000721371-24-000012
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardinal Health elects Robert Azelby to Board of Directors, effective March 1, 2024
--------------------------------------------------------------------------------

- Robert W. Azelby elected as an independent director, effective March 1, 2024.
- Azelby brings over 30 years of biopharma, oncology, and specialty industry experience, including CEO roles.
- He will serve on the Board's Risk Oversight Committee and receive standard non-employee director compensation.
- Azelby currently serves on boards of ADC Therapeutics and Autolus Therapeutics; former CEO of Eliem Therapeutics and Alder BioPharmaceuticals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/721371/000072137124000012/0000721371-24-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/721371/000072137124000012/cah-20240228.htm
  HTML page:      https://secwatch.observer/filing/0000721371-24-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer